<DOC>
	<DOCNO>NCT01666210</DOCNO>
	<brief_summary>To evaluate safety efficacy OTX-DP sustain release drug ( dexamethasone ) depot place canaliculus eyelid treatment ocular inflammation pain subject undergone cataract extraction intra-ocular lens implantation .</brief_summary>
	<brief_title>Phase II Study Evaluating Safety/Efficacy OTX-DP Treatment Ocular Inflammation Pain After Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Capsule Opacification</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Has provide write informed consent , approve appropriate institutional review board ; able comply study requirement visit schedule Is great equal 21 year age Has cataract expect undergo clear corneal cataract surgery phacoemulsification implantation posterior chamber intraocular lens Any intraocular inflammation study eye present screen slit lamp examination Score great `` 0 '' Ocular Pain Assessment Screening Compromised immune system autoimmune disease opinion Investigator could affect quality ocular surface</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>